Get informed when a big investor buys or sells
+ FollowOvervalued by 124.1% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $105.38 Million |
|---|---|
| Enterprise Value | $91.66 Million |
| Earnings per Share | $-0.26 |
| Beta | 2.44 |
| Outstanding Shares | 234,182,284 |
| P/E Ratio | -0.81 |
|---|---|
| PEG | 35.54 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 43.22 |
| Enterprise Value to EBIT | -0.95 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.72 |
| Debt to Equity | 2.12 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 50.83% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 0.27%▼ 37.50% |
|---|---|
| Total Invested | $328,643▼ 99.44% |
| Investors Holding | 10▼ 164.00% |
Alpha Healthcare Acquisition Corp. is a blank check company. The company was incorporated in 2020 and is based in New York, New York.
Stockcircle tracks 5 top investors with a current 13F position in Humacyte. Holdings come from the latest quarterly 13F filings filed with the SEC.
In the latest 13F quarter on Stockcircle, 3 top investors increased or opened positions and 1 top investor reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.
Stockcircle shows 5 open-market insider purchases and 2 open-market insider sales for Humacyte in the last six months from SEC Form 4 reports by executives, directors, and other insiders.
Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.